A Baltimore company in the second phase of a clinical trial for a cancer immunotherapy treatment, one that taps the body’s own immune system to fight disease, has secured $32.5 million in financing to continue developing its products. WindMIL Therapeutics, a Johns Hopkins spinoff company based…
Source: Sun
Baltimore biotech company raises $32.5 million to continue pursuing cancer immunotherapy treatment
Published in Halethorpe
More from HalethorpeMore posts in Halethorpe »
- Maryland State Sen. Clarence Lam joins large field in race for John Sarbanes’ congressional seat
- Catonsville-Arbutus Times 2022-23 high school girls basketball preview: Area teams looking to overcome inexperience
- Charles E. Dutton and Margaret Rose Dutton, couple married for nearly 50 years, die within hours of each other
- The Aegis 2023 high school boys basketball preview: C. Milton Wright is ‘team to beat’
- University of Maryland to launch antisemitism and Islamophobia task force amid increased on-campus tensions
Be First to Comment